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ABSTRACT:  
The present study deals with the formulation and evaluation of Abacavir nanoparticles. Abacavir 
is an antiretroviral drug, it is used in treatment of AIDS. Abacavir  nanoparticles were 
formulated by solvent displacement method using Eudragit RL-100, chitosan and Poloxamer-
188. Nanoparticles were characterized by determining its particle size, drug entrapment 
efficiency, particle morphological character and in-vitro drug release. Particle size range of 
nanoparticles was in the range of 121.4-140.6 nm. Zetapotential of formulations were 
determined, and it was found in range of 16.5-20.45 mv. The in-vitro release of nanoparticles 
were carried out which exhibited a sustained release of Abacavir from nanoparticles up to 10 hrs. 
The study concludes that nanoparticles can be a promising drug delivery system for sustained 
release of Abacavir in terms of increased bioavailability. 
 Keywords: Abacavir, nanoparticles, solvent displacement method, Zeta potential, entrapment 
efficiency, in-vitro release. 
 
INTRODUCTION: 
Nanoparticles are promising drug delivery systems of controlledand targeted drug release. 
Nanoparticles are solid colloidal particles with diameters ranging from 1-1000 nm.  They possess 
unique properties like small size, high surface area, and ease of suspending in liquids, deep 
access to cells and organelles, variable optical and magnetic properties are offered by 
nanoparticles
1
. Their advantages includes increased bioavailability, site specific drug delivery, 
sustained release of drug over longer period of time, retention of dosage form in entire length of 
gastrointestinal tract and convenient to patient due to reduction in dosing frequency
2
. 
Abacavir is a nucleoside analog reverse transcriptase inhibitor (NRTI), antiretroviral drug, it is 
used in treatment of AIDS. It is used together with other HIV medications, and is not 
recommended by itself
3,4,5
.  
MATERIAL AND METHOD: 
Eudragit RL-100 was obtained from Neimeth, and chitosan from Emzor Pharmaceuticals. All 
other chemicals used were of analytical grade. 
Preparation of Abacavir nanoparticles- 
Abacavir nanoparticles were prepared by the solvent displacement method. Drug and various 
proportion of polymers i.e. Eudragit RL-100, and chitosan were dissolved in acetone. This 
solution was poured drop wise into solution of poloxamer 188 with magnetic stirring at room 
temperature. Nanoparticles were spontaneously formed and turnedthe solution slightly turbid 
then; acetone was removed by continuous stirring at 35-40°C. Theprepared suspension was 
centrifuged, supernatant was removed and the sediment was freeze dried for further analysis
6
.  
 
 
 
 
 
  
 
 
Table 1: Composition of different Abacavir nanoparticles  
Formulation 
code 
Eudragit 
RL-100 (mg) 
Chitosan 
(mg) 
Water 
(ml) 
Acetone 
(ml) 
Poloxamer-
188 
(mg) 
NP1 100 - 40 10 10 
NP2 200 - 40 10 20 
NP3 - 100 40 10 30 
NP4 - 200 40 10 40 
 
Particle size, surface morphology and zeta potential- 
The surface morphology (roundness, smoothness, and formation of aggregates) and particle size 
were studied by scanning electron microscopy. Zeta potential is an abbreviation for 
electrokinetic potential in colloidal systems
7
. Zeta potential of theformulations was determined 
by zeta potential probe model DT- 300. 
Drug content- 
The drug content in each formulation was determined by weighing nanoparticles equivalent to 30 
mg of Abacavir and dissolving in 100 ml of 6.8 pH phosphate buffer, followed by stirring. The 
solution was filtered through a 0.45μ membrane filter, diluted suitablyand the absorbance of 
resultant solution was measured spectrophotometrically at 271 nm using 6.8 pH phosphate buffer 
as blank
8
. The drug content of the prepared nanoparticles was determined by the formula: 
% Drug content =(Weight of drug in nanoparticles )/(Weight of nanoparticles) X100 
Nanoparticles recovery  
The recovery of nanoparticles suspension was analyzed by centrifugation method, where 10 mL 
suspension was centrifuged at 15000 rpm at 4°C. The sedimentnanoparticles were collected, 
freeze dried and calculated for % yield
9
. 
% Yield=(Weight of recovered particles)/(Weight of drug and polymer used) X100 
Drug entrapment efficiency 
15 mg of freeze dried nanoparticles were taken in a volumetric flask filled with distilled water 
for extraction of drug and kept for 24 hours. The mixture was sonicated for 20 min. Then filtered 
by using vacuum filter to obtain complete clear solution and samplewill be assayed by UV-
spectrophotometer at 271 nm
10
. The percentage drug entrapment efficiency can be calculated by 
using following equation 
% DEE=(Weight of drug in nanoparticles)/(Weight of drug  used) X100 
In vitro release studies
11 
In vitro release studies were carried out by using dialysis tubes with an artificial membrane. The 
prepared Abacavir nanoparticles and 10 ml of phosphate buffer pH 7.4 was added to the dialysis 
tube and subjected to dialysis by immersing the dialysis tube to the receptor compartment 
containing 250 ml of phosphate buffer pH 6.8. The medium inthe receptor was agitated 
continuously using a magnetic stirrer a temperature was maintained at 37±1°. 5ml of sample of 
receptor compartment were taken at various intervals of time over a period of 24 h and each time 
fresh buffer was replaced. The amount of drug released was determined spectrometrically at 271 
nm. 
Kinetic modeling 
  
In order to understand the kinetic and mechanism of drug release, the result of in vitro drug 
release study of nanoparticles were fitted with various kinetic equation like zero order, first order 
and Higuchi’smodel12. 
RESULT AND DISCUSSION: 
Table 2: Physicochemical characterization of Abacavir nanoparticles. 
Formulation 
code 
Particle size 
(nm) 
% Drug 
content 
% Yield Zeta 
potential 
(mv) 
% 
Entrapment 
efficiency 
NP1 121.4±0.37 70.44±0.26 59.46 16.5±0.52 99.22 
NP2 125.5±0.25 78.32±0.41 64.38 18.31±0.37 99.45 
NP3 130.4±0.71 80.35±0.82 69.57 20.45±0.41 99.92 
NP4 140.6±0.43 84.22±0.31 70.65 19.72±0.73 99.85 
 
 
 
 
Fig 1: % Drug content of Abacavir nanoparticles 
 
Fig 2: % Drug entrapment efficiency of Abacavir nanoparticles 
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Fig 3: SEM of Abacavir nanaoparticles of batch NP4 
 
Four different Abacavir nanoparticles formulations were preparedby the solvent displacement 
method with varying proportions of Eudragit RL-100, and chitosan. 
The scanning electron microphotograph indicate that Abacavir nanoparticles have a discrete 
spherical structure without aggregation.  
The particle size of nanoparticles varied some what among the formulation due to variation in 
the composition of formulations. Particle size range of nanoparticles was in the range of 121.4-
140.6 nm. 
Zeta potential of best formulation was determined and it was found in range of 16.5-20.45 mv. 
Since there was a decrease of surface potential, it could be concluded that a part of drug was 
absorbed on the polymeric particles.  
The drug content was maximum in formulation NP4. In general nanoparticles exhibited an 
increase in drug content with an increased in the polymer ratio, up to particular concentration. A 
decrease in drug content was observed after that point due to the saturation capacity of 
polymer. The percent entrapment efficiency was found to be more than 99 % in all formulations. 
The in-vitro release study was conducted for 10 hrs.The release of Abacavir mainly depend upon 
the polymer concentration. The burst release of Abacavir from nanoparticles at initial stage 
resulted from the dissolution of drug crystals on the surface of nanoparticles. Nanoparticles of 
batch NP3 shows maximum release 82.11%  in 10 hrs.  
  
 
 
Fig-4: In-vitro drug release profile of Abacavir Nanoparticles 
 
 
Table 3: Correlation coefficent of different nanoparticles formulations. 
Formulation code Correlation Coefficient (r
2
 ) 
Higuchi kinetics First order kinetics Zero order kinetics 
NP1 0.993 0.882 0.956 
NP2 0.992 0.884 0.950 
NP3 0.982 0.917 0.893 
NP4 0.976 0.925 0.900 
 
The in vitro release data was applied to various kinetic models to predict the drug release kinetic 
mechanism. Nanoparticles were fitted with various kinetic equation like zero order, first order 
and Higuchi’smodel. The release constant was calculated from the slope of appropriate plots, and 
the regression coefficient (r
2
) was determined by the means of PCP Disso software version 3.0. 
CONCLUSION: 
The method used for preparation of nanoparticles of Abacavir was found to be simple and 
reproducible. The slow and constant release of Abacavir from nanoparticles maintain constant 
drug plasma concentration thereby increasing therapeutic efficacy. The developed formulation 
overcome and alleviates the drawbacks and limitations ofAbacavir sustained release 
formulations. The development of effective nano delivery systems capable of carrying a drug 
specifically and safely to a desired site of action is one of the most challenging tasks of 
pharmaceutical formulation investigators 
On the basis of different parameters i.e. physicochemical and in-vitro release study, 
nanoparticles of batch NP4 are concluded as optimum formulations. 
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Further, it can be concluded that the nanoparticulate formulation can be an innovative and 
promising approach for the delivery of Abacavir. 
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